Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape

Journal of Nanobiotechnology

Miao Fan¹  Xinjian Yang¹  Dandan Han¹  Jinchao Zhang¹  Ruijun Che¹  Tingshan Xiao²  Huifang Liu²  Wei Zhang³  Chi Zhang³  June Wang⁴  Zhenhua Li⁴  Xiaohan Zhou⁴  Hongyu Yan⁴ 

[1] College of Chemistry & Environmental Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Chemical Biology Key Laboratory of Hebei Province, Hebei University;College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University;Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth Peoples’ Hospital;Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan Hospital, Southern Medical University;

关键词: Photosynthetic bacteria;    Hydrogen therapy;    Oxidative stress;    Immune escaped;    Immunotherapy;   

DOI  :  10.1186/s12951-022-01440-7

来源: DOAJ

【 摘 要 】

Abstract Background As an antioxidant, hydrogen (H2) can selectively react with the highly toxic hydroxyl radical (·OH) in tumor cells to break the balance of reactive oxygen species (ROS) and cause oxidative stress. However, due to the high diffusibility and storage difficulty of hydrogen, it is impossible to achieve long-term release at the tumor site, which highly limited their therapeutic effect. Results Photosynthetic bacteria (PSB) release a large amount of hydrogen to break the balance of oxidative stress. In addition, as a nontoxic bacterium, PSB could stimulate the immune response and increase the infiltration of CD4+ and CD8+ T cells. More interestingly, we found that hydrogen therapy induced by our live PSB did not lead to the up-regulation of PD-L1 after stimulating the immune response, which could avoid the tumor immune escape. Conclusion Hydrogen-immunotherapy significantly kills tumor cells. We believe that our live microbial hydrogen production system provides a new strategy for cancer hydrogen treatment combining with enhanced immunotherapy without up-regulating PD-L1. Graphical Abstract

【 授权许可】

Unknown